Shareholders Clear Path for RF Acquisition Corp II–Nanyang Biologics Merger
RFAI sits 42% above its 52-week low of $8.94.
Summary
At the August 19, 2026 meeting, shareholders approved the business combination with Nanyang Biologics. Preliminary redemptions of 3,956,323 shares could substantially reduce the post-merger float.
Key Events · M&A and Partnerships · RFAI
-
Business Combination Approved
The Business Combination Agreement with Nanyang Biologics Pte. Ltd. was approved by a vote of 6,765,584 for and 440,604 against.
-
Preliminary Redemptions of 3.96M Shares
Preliminary requests to redeem 3,956,323 RFAC Ordinary Shares have been submitted, subject to withdrawal or reversal prior to Closing.
-
Deal Terms and Timeline
The Business Combination Agreement is dated October 2, 2025, and the Definitive Proxy Statement/Prospectus was filed July 27, 2026. Closing remains subject to satisfaction or waiver of conditions.
-
Post-Merger Governance Approved
Advisory governance proposals, including authorized share capital of 500M ordinary shares and 100M preference shares, were approved.
Analysis · RFAI · Real Estate & Construction
A major hurdle for the SPAC's merger has been cleared: shareholders voted overwhelmingly to approve the business combination with Nanyang Biologics Pte. Ltd. The tally was 6,765,584 for and 440,604 against, with 86.36% of shares represented. Preliminary redemption requests total 3,956,323 shares, which would leave a significantly reduced public float if finalized. While closing conditions still need to be met, this approval marks a critical step toward completing the transaction.
At the time of this filing, RFAI was trading at $12.73 on NASDAQ in the Real Estate & Construction sector, with a market capitalization of approximately $106.2M. The 52-week trading range was $8.94 to $12.73. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.